Browse studies

Find your next paid study

27,306 recruiting studies available now

A Pilot Study of Pembrolizumab in Combination With Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma

This research study is studying if the investigational drug, Pembrolizumab, in combination with chemotherapy helps primary central nervous system lymphoma with…

LymphomaPrimary Central Nervous System Lymphoma

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT06475235

Phase 1

A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics

The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendatio…

Hepatic Impairment

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07872033

Phase 2

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Immunoglobulin A Nephropathy (IgAN)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07146906

Double Lung Transplant REgistry Aimed for Lung-limited Malignancies (DREAM) - a Prospective Observational Registry Study for Patients Undergoing Lung Transplantation for Medically Refractory Cancers Confined to the Lungs

This is a prospective observational registration trial for patients who undergo lung transplantation for the treatment of the select groups of medically refrac…

Lung CancerBilateral CancerLung Transplant

Estimated

~$10 – $750

Actual pay is set by the research site.

Northwestern UniversityNCT05671887

Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome

Background: \- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or conne…

Li-Fraumeni SyndromeNeoplasmsTp53 Mutations

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT01443468

Phase 2

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with l…

Low-Grade Serous Ovarian Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT06394804

Phase 2

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK wor…

Lymphoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT02974647

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7262 as Monotherapy and When Coadministered With Enlicitide Decanoate in Adults With Elevated Lipoprotein(a)

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial m…

Lipoprotein(a)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07614984

Observational

Social Cognitive Training to Enhance the Efficacy of CBT forDepression in Youth: A Developmental Approach (R33)

Depression in youth is a serious public health concern for which more personalized treatments are needed. This randomized controlled trial will test the effect…

Depression

Estimated

~$10 – $750

Actual pay is set by the research site.

Vanderbilt UniversityNCT05456035

Phase 1

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer

This phase 1 study evaluates the safety, efficacy, and biological activity of GB-5267 in patients with platinum-resistant ovarian cancer.

Platinum-resistant Ovarian Cancer

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Roswell Park Cancer InstituteNCT07489287

Phase 1

A Phase 1 Study of Oral Cedazuridine and Decitabine Combination (ASTX727, NSC# 820631) and Filgrastim as Maintenance Therapy Post-Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia …

Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07012044

Observational

Randomized Trial of Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening

The project will investigate the efficacy of a Veteran-peer-navigator-led decision coaching (PDC) program to promote Shared Decision Making (SDM) for prostate …

Prostate Cancer

Estimated

~$10 – $675

Actual pay is set by the research site.

VA Office of Research and DevelopmentNCT06549036